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Context: The contribution of autoimmunity to the multisystem dysregulation that characterizes
the frailty syndrome in older adults is unknown.
Objective: The aim of the study was to investigate the relationship between thyroid antibodies and
frailty in older women.
Design, Setting, and Participants: We conducted a cross-sectional study nested within the Women’s
Health and Aging Studies I and II. Thyroglobulin antibodies (TgAbs), thyroid peroxidase antibodies
(TPOAbs), and antinuclear antibodies were measured in the baseline sera of 641 community-
dwelling older women.
Main Outcome Measure: Frailty was defined using a validated five-component measure.
Results: The prevalence of prefrailty and frailty was lower in TgAb-positive than negative older
women (37.1 vs. 47.8% and 6.7 vs.11.9%, respectively; P  0.01 and 0.03). The prevalence of
prefrailty, but not frailty, was lower in TPOAb-positive than negative women (38.9 vs. 48.0% and
10.1 vs. 11.3%; P  0.04 and 0.34). After adjustment for covariates including serum thyroid stimulation
hormone concentration and thyroid medication usage in multinomial regression models, TgAb-pos-
itiveolderwomenhadloweroddsofprefrailtyandfrailtycomparedwithTgAb-negativewomen(odds
ratio 0.57 and 0.30; 95% confidence interval 0.34–0.98 and 0.10–0.85, respectively). Similarly, TPOAb-
positive older women had lower odds of frailty compared with TPOAb-negative women (odds ratio
0.44;95%confidence interval0.20–0.96).Thesetrendswerenotobservedwithantinuclearantibodies.
Conclusion: Independent of thyroid function status, community-dwelling older women who are
seropositive for TgAbs and TPOAbs are less likely to be frail than seronegative women. (J Clin
Endocrinol Metab 95: 1161–1168, 2010)
Frailty is a geriatric syndrome affecting approximately7–17% of older adults older than 65 yr of age and
25–30% of those older than 85 yr (1–4). It has been char-
acterized as a state of decreased physiological reserve, loss
of physiological complexity, and accumulation of deficits
(1, 5, 6) and is an independent risk factor for adverse
outcomes in older adults (1, 2, 4). The emergence of op-
erational definitions of frailty has permitted a standard-
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ized approach to the epidemiological and pathophysio-
logic investigations of this common geriatric syndrome
(1–3, 7). Distinguished from disability and comorbidity
(8) and theorized as a clinical syndrome of energy dys-
regulation (1, 2), frailty has been cross-sectionally asso-
ciated with elevated levels of serum IL-6 and C-reactive
protein (9). These observations have led some investiga-
tors to hypothesize that inflammation, above and beyond
that hypothesized to accompany aging (10), plays a role in
the pathogenesis of frailty through its effects on multiple
physiological systems (8, 9, 11). Little is known regarding
the relationship between autoimmunity and frailty in
older adults. Because a close clinicopathological associa-
tion exists between inflammation and autoimmunity (12),
we hypothesized that autoimmunity, triggering or trig-
gered by inflammation, might contribute to the develop-
ment of frailty in some older adults.
Autoimmunity arises out of dysregulation in immuno-
regulatory mechanisms that result in the breakdown of
self-tolerance and production of self-reactive autoanti-
bodies (13). Thyroid autoimmunity is the paradigm of
organ-specific autoimmunity. Thyroglobulin antibodies
(TgAbs) and thyroid peroxidase antibodies (TPOAbs) are
found in 11.2 and 11.9% of 30- to 39-yr-old adults, and
prevalence increases with age to 18.8 and 22.3% of 70- to
79-yr-old adults in the United States (14). Individuals har-
boring either TgAbs or TPOAbs are more likely to have
abnormal serum concentrations of TSH (15). Because of
the fundamental role of the thyroid gland in regulating
metabolism and energy homeostasis (16), we hypothe-
sized that thyroid autoimmunity would be associated with
frailty, either through direct pathological effects of the au-
toreactive T cells or autoantibodies or indirectly through pri-
mary changes in thyroid function. To test this hypothesis, we
measured TgAbs and TPOAbs in a well-characterized pop-
ulation of community-dwelling older women in whom
frailty status was rigorously measured.
Subjects and Methods
Study population
This cross-sectional study involved 641 older women who
participated in the Women’s Health and Aging Studies (WHAS)
I and II, two complementary prospective observational studies of
women living in the community (17, 18). WHAS I enrolled
women aged 65 yr and older who had self-reported difficulty in
two or more of four domains of physical function. WHAS II
enrolled women aged 70–79 yr who had difficulty in no more
than one domain. Both cohorts were sampled from the same
sampling frame, the Health Care Financing Administration’s
Medicare eligibility lists for Baltimore, MD. Details on the study
methods and sampling design of WHAS have been published
elsewhere (17, 18). WHAS I enrolled 1002 women, of whom 672
participated in blood drawing. WHAS II enrolled 436 women,
93% of whom participated in blood drawing. Women who did
and did not participate in blood drawing were different by age
(76.3 vs. 80.8 yr, respectively; P  0.0001) and prevalence of
cardiovascular disease (51.3 vs. 61.4%, respectively; P  0.02).
For both cohorts, diagnoses of 17 major chronic diseases were
adjudicated by physicians using ascertainment algorithms (17).
The Johns Hopkins University’s Institutional Review Board ap-
proved all research protocols. Informed consent was obtained
from all participants.
The population for the present study was derived by com-
bining WHAS I and II and including women from WHAS I only
if they were in the same age range as those in WHAS II (70–79
yr). Of the 829 eligible women, 667 had baseline serum speci-
mens available for the detection of autoantibodies, all of whom
except seven had complete data on frailty measures. Of these, 11
and eight were missing baseline IL-6 and TSH measurements,
respectively. A resultant final sample size of 641 for this study
consisted of 276 WHAS I and 365 WHAS II participants.
Definition and classification of frailty
We defined frailty using a five-component measure that was
originally proposed in the Cardiovascular Health Study (1) and
subsequently validated in WHAS (2). The five components, each
a binary criterion measured using standardized questions or pro-
tocols, consist of: 1) shrinking, defined as unintentional weight
loss of 10% or more since age 60 yr or body mass index less than
18.5 kg/m2; 2) exhaustion, defined as self-report of having low
usual energy level (3 on a 0–10 scale), feeling unusually tired
in the last month, or feeling unusually weak in the last month; 3)
low energy expenditure, defined as being in the lowest quintile of
energy expenditure measured using a six-item version of the
Minnesota Leisure Time Activity Questionnaire (17); 4) slow-
ness, defined as being in the lowest quintile of walking speed over
a 4-m distance; 5) weakness, defined as being in the lowest quin-
tile of hand grip strength measured using a Jamar handheld dy-
namometer (model BK-7498; Fred Sammons, Inc., Burr Ridge,
IL). Participants meeting three or more of these criteria were
classified as frail; those meeting one or two as prefrail; and those
meeting none as nonfrail.
Laboratory measurements
Serum and plasma were separated from nonfasting venous
blood samples using centrifugation and stored at 70 C until the
time of analysis. Serum TgAbs and TPOAbs and antinuclear
antibodies (ANAs) were measured using commercial ELISA kits
(QUANTA Lite Thyroid T, TPO, and ANA, respectively;
INOVA Diagnostics, San Diego, CA). Plasma IL-6 was measured
using a commercial ELISA kit (Quantikine human IL-6; R&D
Systems, Minneapolis, MN). Serum TSH was measured using an
immunochemiluminometric assay (Ciba Corning Diagnostic
Corp., Medfield, MA) by Quest Diagnostic Laboratories (Teter-
boro, NJ). All assays were performed while masked to frailty
status.
For both TgAbs and TPOAbs, we defined a titer of 62.5 or
greater and less than 100 World Health Organization (WHO)
units as being moderately positive and 100 or more WHO units
as strongly positive. For ANAs, we defined a titer of 20 U or
greater as being moderately positive and 60 U or greater as
strongly positive. These cutoffs for autoantibody positivity were
specified by the manufacturer. In regression analyses, we defined
autoantibody positivity as being at least moderately positive. In
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sensitivity analyses, we examined the robustness of our results by
redefining antibody positivity as being strongly positive only.
Covariates
Age, strongly associated with both frailty (1, 4) and thyroid
autoimmunity (14), was represented as a continuous variable.
Race and education, both associated with frailty (1, 4), could
serve as surrogate markers of the socioeconomic environment
that could influence the development of thyroid autoimmunity
(19). Race was coded as a categorical indicator variable (white,
black, American Indian or Alaskan Native, or Asian or Pacific
Islander). Education was coded as a categorical indicator vari-
able (completed 0–8th grade, 9–11th grade, 12th grade or GED,
or 12th grade or GED). Body mass index (BMI), associated
with both thyroid autoimmunity and frailty (4, 20), was coded
as a continuous variable. Thyroid antibody concentration was
reported to decrease on T4 replacement therapy (21). Thyroid
medication usage, coded as a binary variable, included thyroid
hormone preparations or antithyroid drugs; no participants used
amiodarone at baseline. Smoking, associated with both frailty
(4) and lower prevalence of thyroid antibodies (22), was coded
as a categorical indicator variable (never smoker, former smoker
who quit 1 yr ago, former smoker who quit 1 yr ago, or
current smoker). Type 1 diabetes and thyroid autoimmunity are
related by likely similar immunoregulatory and genetically sus-
ceptible mechanisms (23), and type 2 diabetes has been associ-
ated with thyroid autoimmunity (24); diabetes was coded as a
binary variable. Potential associations exist between thyroid an-
tibodies and cardiovascular disease (25), which in turn has been
associated with frailty (26). Cardiovascular disease was coded as
a single binary variable representing the diagnosis of angina,
myocardial infarction, peripheral arterial disease, congestive
heart failure, or stroke. In this study, diseases were considered
present if classified as definite or probable by adjudication or as
self-reported for nonadjudicated diagnoses. IL-6, a cytokine that
has been observed to be elevated in frail older adults, including
those in WHAS (6), and might play a role in thyroid autoimmu-
nity (27), was coded as logarithm-transformed continuous
variable.
Statistical analysis
Baseline characteristics between women with and without
thyroid antibodies were compared, using Student’s t test for con-
tinuous variables and the 2 test for categorical variables. Asso-
ciations between autoantibody prevalence and frailty status were
tested using the 2 test. Multinomial logistic regression models
were constructed to assess the effect of thyroid antibodies on the
odds of being frail or prefrail vs. nonfrail in unadjusted and
adjusted models. Potential confounders included as covariates in
the regression models were age, race, education, thyroid medi-
cation usage, smoking, diabetes mellitus, cardiovascular disease,
and plasma IL-6 concentration. In addition to these two models
(unadjusted and adjusted), we constructed a third model in
which a term for logarithm-transformed serum TSH concentra-
tion was added to the adjusted model.
Probability weights were calculated and incorporated into all
descriptive and regression analyses to reference inferences to the
population of community-dwelling women aged 70–79 yr (28).
P  0.05 was considered statistically significant for all analyses,




Overall, women participating in WHAS I and II with
positive thyroid antibodies (TgAbs or TPOAbs, n  175)
had similar baseline characteristics to women with nega-
tive thyroid antibodies (n  466, Table 1). Exceptions
were higher percentages of women taking a thyroid med-
ication (P  0.001) or having abnormal serum TSH (P 
0.003) in the thyroid antibody-positive group (Table 1).
Relationships between autoantibodies and frailty
in community-dwelling older women
We determined the percentages of women who were
nonfrail, prefrail, and frail according to TgAb or TPOAb
seropositivity. As shown in Table 2, a significantly smaller
percentage of TgAb-positive women were prefrail or frail,
compared with TgAb-negative women (37.1 vs. 47.8%
and 6.7 vs. 11.9%, respectively; P  0.01 and 0.03). The
prevalence of prefrailty, but not frailty, was lower in
TPOAb-positive than -negative women (38.9 vs. 48.0%
and 10.1 vs. 11.3%; P  0.04 and 0.34).
We then compared the prevalence of TgAbs and
TPOAbs across women classified with incremental states
of frailty, i.e. women who were nonfrail, prefrail, and frail.
Figure 1A demonstrates that the prevalence of TgAbs
(moderate or strong positivity) was higher in nonfrail
women (22.7%) than prefrail (14.0%; P  0.01) or frail
women (10.6%; P  0.03). The prevalence of TPOAbs in
nonfrail women (27.5%) was higher than in prefrail
women (19.7%; P  0.04) but was not statistically sig-
nificantly higher than in frail women (21.4%; P  0.34;
Fig. 1B).
To investigate whether the lower prevalences of thyroid
antibodies in prefrail and frail women when compared
with nonfrail women was a generalized phenomenon af-
fecting other autoantibodies or a unique one restricted to
TgAbs and TPOAbs, we measured serum ANA titers in the
same population of WHAS participants. ANA was chosen
because, as a commonly measured autoantibody, it can be
found to be elevated at low dilutions (1:40) in up to 50%
of the population (29). Because the assay we used captures
antibodies to a variety of autoantigens (chromatin, dsDNA,
Sm/RNP, SS-A, SS-B, Scl-70, centromere, PCNA, Jo-1, mi-
tochondrial M-2, and ribosomal P protein), the test served
well to represent a nonthyroidal, systemic autoantibody for-
mation. Figure 1C shows that, in contrast to thyroid anti-
body prevalences, ANA prevalence (moderate or strong pos-
itivity) did not decrease from nonfrail to frail states but were
actually higher in prefrail (54.3%) than nonfrail women
(44.6%;P0.04)andnotstatisticallydifferentbetweenfrail
and nonfrail women.
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Odds of being prefrail and frail in
community-dwelling older women possessing
thyroid antibodies
The effect of thyroid antibody presence on the odds of
being prefrail or frail in older women was assessed using
multinomial logistic regression models. For women who
were positive for TgAbs, their likelihood of being prefrail or
frail, compared with that of being nonfrail, was incremen-
tally lower, respectively (Table 3). These lower odds per-
sisted, even after adjusting for age, race, education, BMI,
thyroidmedicationusage, smoking,diabetes, cardiovascular
disease, and IL-6 concentration, such that the odds ratio
(OR) of being prefrail was 0.56 [95% confidence interval
(CI) 0.33–0.94] and being frail was 0.29 (95% CI 0.10–
0.83). Because thyroid antibodies have been reported to be
associated cross-sectionally and longitudinally with thyroid
dysfunction (14, 30), we added serum TSH concentration to
the adjusted model to assess whether the observed associa-
tions between thyroid antibodies and frailty were indepen-
dent of TSH concentration. As shown in Table 3, the lower
odds of being prefrail and frail in women with TgAbs
persisted after adjusting for TSH. Similarly, women
with TPOAbs had a lower adjusted odds of being prefrail
(OR 0.59; 95% CI 0.36–0.94) and an even lower adjusted
odds of being frail (OR 0.45; 95% CI 0.21–0.95). In these
women, similar trends in lower odds persisted after addi-
tionally adjusting for TSH, but the 95% CI for the OR re-
lating TPOAbs to prefrailty contained the null value.
TABLE 2. Prevalence of frailty by status of autoantibody seropositivity in WHAS I and II
Autoantibody Frailty status
Presence of thyroid antibodiesa
P valuebPositive Negative
TgAb Nonfrail, n (%)c 59 (56.2) 204 (40.3)
Prefrail, n (%) 44 (37.1) 258 (47.8) 0.01
Frail, n (%) 8 (6.7) 68 (11.9) 0.03
Total 111 (100) 530 (100)
TPOAb Nonfrail, n (%) 71 (51.0) 192 (40.7)
Prefrail, n (%) 60 (38.9) 242 (48.0) 0.04
Frail, n (%) 15 (10.1) 61 (11.3) 0.34
Total 146 (100) 495 (100)
a Positivity for thyroid antibody was defined as a titer of 62.5 or more WHO units.
b P values were calculated against the nonfrail group with the use of  2 test.
c Study-specific probability weights were used to reference the percentages in the sampling population-to-population representation.
TABLE 1. Baseline characteristics of the study participants in WHAS I and II (n  641)
Characteristic
Presence of thyroid antibodies
(TgAb or TPOAb)a
Positive
(n  175, 27.8%)b
Negative
(n  466, 72.2%) P valuec
Age (yr) 73.9  2.8 74.0  2.7 0.88
White race, n (%) 135 (78.4) 352 (76.4) 0.62
Thyroid medication use, n (%) 31 (17.2) 36 (7.6) 0.001
Serum TSH concentration (mU/liter)d 2.7 (3.0) 1.9 (2.0) 0.001
Abnormal, n (%)e 34 (18.1) 48 (9.8) 0.003
BMI (kg/m2) 27.1  5.9 27.7  6.2 0.30
High school education, n (%) 103 (58.7) 265 (58.1) 0.89
Current or former smoking, n (%) 85 (48.0) 245 (50.7) 0.58
Diabetes mellitus, n (%) 20 (10.4) 77 (15.3) 0.11
Angina pectoris, n (%) 34 (20.5) 102 (21.9) 0.74
Myocardial infarction, n (%) 21 (12.6) 52 (11.4) 0.69
Congestive heart failure, n (%) 21 (10.8) 76 (15.1) 0.16
Osteoarthritis, n (%) 134 (76.6) 333 (71.7) 0.24
Osteoporosis, n (%) 79 (46.6) 191 (41.0) 0.23
History of stroke, n (%) 12 (8.0) 38 (8.2) 0.94
Pulmonary disease, n (%) 64 (36.9) 188 (39.9) 0.51
Plasma IL-6 concentration (pg/ml)e 3.2  2.0 3.8  5.8 0.48
Continuous variables are presented as means  SD, whereas categorical variables are presented as counts and percentages.
a Positivity for the presence of thyroid antibody was defined as a titer of 62.5 or more WHO units; b study-specific probability weights were used to
reference the percentages in the sampling population-to-population representation; c P values were calculated with the use of t test for continuous
variables and  2 test for binary variables; d abnormal serum TSH concentration was defined as less than 0.45 or greater than 4.5 mU/liter; e P
values were calculated with the use of Mann-Whitney test because of skewed distributions.
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To determine whether the lower odds of being pre-
frail and frail in the presence of autoantibodies were
unique to thyroid antibodies, we constructed similar
multinomial logistic regression models, which incorpo-
rated ANA as the predictor variable. In contrast to thy-
roid antibodies, seropositivity for ANA in older women
was associated with higher crude and adjusted odds of
being prefrail (but not when TSH was added to the
model) and was not significantly associated with the
odds of being frail (Table 3).
We performed sensitivity analyses to test the robustness
of these results by redefining antibody positivity as being
stronglypositive;womenwhoseantibody titersweremod-
erately positive were redefined as being seronegative. In
both adjusted models (without and with TSH), the mag-
nitudes of the ORs for thyroid antibodies remained similar
to analyses in which antibody positivity was defined as
being moderately or strongly positive (data not shown).
The P values of the association between TgAbs and frailty
increased to 0.05 and 0.06 in the adjusted models without
and with TSH, respectively. The P values of
the association between TPOAbs and frailty
decreased to 0.03 and 0.03. The relationship
between ANA and frailty remained insignif-
icant, the P values being 0.48 and 0.49 be-
tween ANA and prefrailty and 0.78 and
0.83 between ANA and frailty.
We performed further sensitivity analy-
ses by excluding women who were taking
thyroid medications (n  80) and repeating
the regression analyses above. The magni-
tudes of the ORs remained similar to anal-
yses that included thyroid medication users.
The associations remained significant be-
tween TgAbs and frailty but were attenu-
ated between TgAbs and prefrailty and be-
tween TPOAbs and prefrailty and frailty (data not
shown), as would be expected from a 12% decrease in
sample size.
Relationship between thyroid antibody
seropositivity and serum TSH concentration
Older women in the combined WHAS I and II pop-
ulation who were seropositive for thyroid antibodies
and not taking thyroid hormones were more likely to
have abnormal TSH concentrations (P  0.001; Table
4). A direct comparison with the study sample from the
National Health and Nutrition Examination Survey
(NHANES) III is not possible because of the inclusion of
men in age-specific data or lack of age-group separation
in gender-specific data in the published tables (15, 31).
Nevertheless, the prevalence distribution across differ-
ent TSH concentration groups among thyroid antibody-
positive individuals in our study population follows a
trend similar to that observed in NHANES III.
FIG. 1. Prevalence of autoantibodies in women of incremental states of frailty in WHAS
I and II. Shaded regions in bars indicate percentage of women within the respective
frailty-status group who were seropositive for TgAbs (A),TPOAbs (B), and ANAs (C).
Study-specific probability weights were used to derive the percentages. P values were
determined by the 2 test.








Adjusted model with TSH
(n  641)b
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
TgAb Nonfrail 1.00 1.00 1.00
Prefrail 0.56 (0.35–0.89) 0.01 0.56 (0.33–0.94) 0.03 0.57 (0.34–0.98) 0.04
Frail 0.40 (0.18–0.91) 0.03 0.29 (0.10–0.83) 0.02 0.30 (0.10–0.85) 0.02
TPOAb Nonfrail 1.00 1.00 1.00
Prefrail 0.65 (0.42–0.99) 0.04 0.59 (0.36–0.94) 0.03 0.62 (0.38–1.01) 0.06
Frail 0.72 (0.37–1.41) 0.34 0.45 (0.21–0.95) 0.04 0.44 (0.20–0.96) 0.04
ANA Nonfrail 1.00 1.00 1.00
Prefrail 1.47 (1.03–2.12) 0.04 1.46 (0.97–2.17) 0.07 1.44 (0.96–2.15) 0.08
Frail 1.07 (0.62–1.84) 0.81 1.01 (0.54–1.91) 0.97 1.01 (0.53–1.91) 0.98
a Adjusted for age, race, education, BMI, thyroid medication usage, smoking, diabetes mellitus, cardiovascular disease, and IL-6 concentration with
the use of multinomial logistic regression modeling.
b Adjusted for all of the covariates above and TSH.
c Positivity for autoantibody was defined as a titer of 62.5 or more WHO units for Tg and TPO Ab and 20 U or greater for ANA.
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Discussion
In this study, we measured serum TgAbs and TPOAbs in
a population of community-dwelling older women well
characterized in their frailty status. We found that older
women seropositive for TgAbs were less likely to be pre-
frail and frail in a graded manner. A similar trend was
noted for TPOAbs, except that its relationship with pre-
frailty was not statistically significant after adjustment for
serum TSH. To determine whether the decreased likeli-
hood of frailty associated with thyroid antibody presence
would extend to other autoantibodies, we further mea-
sured a systemic marker of autoantibody, ANA, in the
same population of older women. In contrast to thyroid
antibody findings, we found that women seropositive for
ANA did not have decreased odds of being frail or prefrail.
To the authors’ knowledge, this is the first study that dem-
onstrated a specific, inverse association between thyroid-
specific antibodies and the frailty syndrome.
The cross-sectional nature of this study precludes in-
ferenceson the causalityunderlying thepresentlyobserved
association between thyroid antibodies and frailty. It is
unclear whether these autoantibodies are pathogenic or
mere bystanders in this geriatric syndrome. Several pos-
sible explanations can be provided for this finding.
First, the decreased prevalence of thyroid antibodies in
frail older women could suggest a generalized immuno-
deficiency globally affecting the production of antibodies.
The previously reported higher prevalence of IgG anti-
bodies against cytomegalovirus in frail older women (32)
refutes this hypothesis. Alternatively, a deficiency limited
to autoantibody production could be postulated. How-
ever, the lack of an association between a classical auto-
antibody, ANA, and frailty suggests that the lower prev-
alence of autoantibodies in frail older women is restricted,
at least in this study, to thyroid antibodies. It is conceivable
that differences in the mechanisms of thyroid and antinu-
clear antibody production could affect frail and nonfrail
older adults differentially. In the case of TgAbs, at least,
the antibody titer corresponds to thyroglobulin concen-
tration (33). Whether frail older women might have de-
creased thyroglobulin concentration or thyroid mass,
thereby potentially affecting thyroid antibody generation,
is unknown. Although we do not believe that the data
reported here reflect a generalized immunodeficiency af-
fecting frail older women, further studies are needed to
determine whether an immunologically mediated mecha-
nism underlies the lower prevalence of thyroid antibodies
in these women.
Second, a beneficial effect of thyroid antibodies on the
pathogenesis of frailty could also be envisioned. The con-
cept of beneficial autoimmunity was raised more than 3
decades ago in the context of antiidiotype antibody re-
sponses (34). Recent findings reveal that patients with
rheumatoid arthritis produce a self-reactive antibody that
neutralizes the proinflammatory mediator, TNF- (35).
These self-reactive antibodies are of the IgG isotype and
are very specific, interacting with three determinants on
the TNF- molecule that display no cross-reactivity to any
other known gene product (35). On the other hand, au-
toantibodies that occur in healthy individuals, referred to
as natural autoantibodies, are usually of the IgM isotype
and bind to several unrelated antigens with moderate af-
finity (36). Natural autoantibodies have a role in the de-
velopment of the B cell repertoire and the homeostasis of
the immune system (37). For example, rheumatoid factor
has been suggested to enhance the binding of low-affinity
IgG antibodies to their antigens (38), thereby potentially
assisting in first-line immunological defense against for-
eign pathogens before the development of specific, higher-
affinity antibodies. The thyroid antibodies, however, do
TABLE 4. Prevalence of thyroid antibodies according to category of TSH concentration in WHAS I and IIa
Thyroid antibodiesb




(n  20, 2.9%)
0.4–2.49
(n  413, 71.7%)
2.5–4.5
(n  108, 19.6%)
Greater than 4.5
(n  33, 5.8%)
TgAb, n (%)d 0.001
Positive 2 (1.9) 51 (55.3) 24 (25.1) 16 (17.8)
Negative 18 (3.1) 362 (74.8) 84 (18.5) 17 (3.5)
TPOAb, n (%) 0.001
Positive 2 (1.4) 64 (53.2) 33 (29.0) 15 (16.4)
Negative 18 (3.3) 349 (76.7) 75 (17.1) 18 (3.0)
Either TgAb or TPOAb, n (%) 0.001
Positive 2 (1.2) 85 (57.5) 38 (27.2) 19 (14.1)
Negative 18 (3.5) 328 (76.6) 70 (16.9) 14 (2.9)
a Women who were taking thyroid hormones were excluded; b positivity for TgAbs and TPOAbs was defined as a titer of 62.5 or more WHO units;
c P values were calculated with the use of  2 test; d percentage within the respective thyroid antibody serostatus group. Study-specific probability
weights were used to reference the percentages in the sampling population-to-population representation.
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not fit readily into either of these classifications of poten-
tially beneficial autoantibodies. Other than their specific-
ity for thyroglobulin or thyroid peroxidase, the two thy-
roid antibodies tested in this study are not known, to date,
to bind to any proinflammatory or cytotoxic mediator
that might have a detrimental effect on the health of in-
dividuals who harbor them. Therefore, it remains to be
elucidated how thyroid antibodies might interact with the
process of induction or maintenance of the frailty syn-
drome and whether some form of beneficial autoimmunity
might be at play.
Third, confounding by differences in baseline charac-
teristics, uncontrolled confounders, or residual confound-
ing between participants with and without thyroid anti-
bodies is possible. As expected, the group of WHAS
participants seropositive for thyroid antibodies had a
higher prevalence of abnormal serum TSH concentration.
However, the inverse association between thyroid anti-
bodies and frailty persisted after adjusting for TSH in the
regression models and is therefore statistically indepen-
dent of TSH concentration. In addition, the higher prev-
alence of thyroid medication usage in thyroid antibody-
positive women might be a surrogate marker of better
clinical follow-up or better social or family support and
thus represents a lower frailty risk (39). However, the in-
verse association between thyroid antibodies and frailty
persisted, even after we adjusted for thyroid medication
usage in the regression models. Nevertheless, we recognize
the possibility of residual or uncontrolled confounding,
such as the lack of data on iodine status.
It is conceivable that the phenomenon observed here
might reflect an exhaustion of thyroid autoimmunity,
prevalent in older age (14), in frail older women. A pos-
sible pathway to such an exhaustion of thyroid autoim-
munity would be the depletion of thyroid antigen by an
ongoing autoimmune response on the thyroid gland (40).
Such a hypothesis is consistent with the observation of
elevated serum concentrations of inflammatory biomar-
kers in frail older adults (9). A lower thyroid antigenic
mass and the concomitant compromise in the important
role of the thyroid gland in maintaining energy homeosta-
sis (16) could, in turn, be consistent with the conceptual-
ization of frailty as a clinical syndrome of energy dysregu-
lation (1, 2). Therefore, more mechanistic studies are
warranted to clarify the pathophysiological mechanisms
driving the inverse association between TgAb prevalence
and frailty reported here.
Several strengths of this study lend support to the in-
ferences herein derived. We used a large, well-character-
ized population of community-dwelling older women en-
compassing a range of disability (17, 18). The definition of
frailty used in this study is a well-validated measure (1, 2,
8). The usage of study-specific probability weights enables
extrapolation of the results to a larger population (28).
Finally, among thyroid antibody-positive individuals in
our study population, the prevalence distribution across
different TSH concentration groups follows a trend sim-
ilar to that observed in NHANES III.
In conclusion, we report for the first time a graded in-
verse association between seropositivity for TgAbs and
TPOAbs and the likelihood of prevalent frailty in older
women. Whether this finding originates from differences
in immune system function and homeostasis among
women classified as nonfrail, prefrail, and frail or it re-
flects changes in the thyroid target organ remains to be
elucidated. Replication of our results in another popula-
tion is essential in guiding further research.
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